There have been a number of significant recent developments that will be of interest to women who have suffered serious health problems caused by their use of Yaz and Yasmin oral contraceptives.
These stem from the controversy over the safety of the drugs, which respected medical researchers, the U.S. Food and Drug Administration, consumer groups and allegations contained in Yaz and Yasmin lawsuits claim put women at higher risk of suffering blood clots, pulmonary embolisms and deep vein thrombosis.
These developments have been culled from media outlets, medical journals and informational web sites:
- One of the most respected medical organizations in the country, the American College of Obstetricians and Gynecologists, joined in the chorus of warnings about the dangerous side effects of Yaz and Yasmin. The physicians’ group is now warning that the Yaz and Yasmin birth control pills and generics may be putting women at a higher risk of suffering blood clots than other oral contraceptives.
- Researchers from the University of Copenhagen have published results of a study on the Yaz and Yasmin class of birth control pills that was published in the British Medical Journal and shows that women are at higher risk of blood clotting.
- The Food and Drug Administration made public research from a study that the agency funded entitled “Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints” that follows up on earlier warnings about the safety of the drugs and shows that contraceptives like Yaz could put women at as much of a 74 percent increase in risk of suffering blood clots, deep vein thrombosis and pulmonary embolism.
- The New York Times confirmed in one of its articles that the FDA sent a warning letter to the manufacturer of Yaz and Yasmin, German pharmaceutical giant Bayer, criticizing the company for not providing greater emphasis on warning patients about the dangerous side effects that the drugs could cause.
- The FDA, acting in response to a growing number of adverse event reports updates the warning labels on Yaz, Yasmin and other contraceptives containing drospirenone to reflect the fact that taking those pills could put women at three times the risk of suffering a blood clot than women not using pills containing drospirenone.
- Federal court officials now estimate that over 10,000 women have filed claims in connection with Yaz and Yasmin multi-district litigation now being coordinated by a judge in Illinois presiding over allegations of dangerous side effects from the pills.
- Bayer confirms published reports documenting that the company has spent nearly $150 million to settle some of the thousands of lawsuits filed against it over Yaz and Yasmin side effects and financial media experts estimate that eventual legal costs in the litigation may soar into the billions of dollars.
- Even as a federal judge authorizes Bayer to enter into settlements with women who filed Yaz and Yasmin lawsuits over adverse side effects lawyers for these women announce that they are still accepting cases from other women who have yet to file claims over the serious Yaz and Yasmin health problems they have suffered.
- Amid its massive legal expenses in dealing with Yaz and Yasmin lawsuits as well as litigation over other products, Bayer recently reported to investors that it has suffered a third-quarter drop of 18 percent in net income.